Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

Adeona Pharmaceuticals, Inc. (Amex: AEN) announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, has expanded its in-house diagnostic testing services to include a full array of microbiology testing.  Adeona believes that that this expansion of services will be accretive to HartLab's revenues in the current quarter and beyond and is consistent with Adeona's plans to continue to build the revenues of its HartLab subsidiary.

Microbiology testing includes a broad array of tests for the identification and sensitivity testing of the causative agents of infectious diseases followed by prompt, accurate reporting of results. HartLab has the ability to develop and implement new culture techniques, immunoassays, and molecular methods for rapid detection and identification of common as well as unusual microbial pathogens. Serologic testing is also available for confirmation of infections by demonstrating the presence of specific antibody responses.

As part of its new microbiology department, HartLab has hired Mariana Badescu, MD, PhD, as Technical Supervisor and Mihai Badescu, BS, MA, M(ASCP), as Lead Microbiology Technologist. Dr. Badescu, a certified Specialist in Microbiology and Public Health, comes to HartLab with over 20 years of microbiology laboratory experience and infection control.

"Offering our clients a comprehensive array of clinical testing services under one roof has been a long-term goal for us," said Lisa Jo Abbo, Vice President of HartLab. "We are glad we can add further value to the relationships we have developed with our physician clients and believe these additional services will make HartLab more competitive when it comes to attracting new clients."